tiprankstipranks
Advertisement
Advertisement

ONC Stock Latest News

BeOne Medicines Completes First-in-Human Study of New B7H3 Cancer Drug
Company AnnouncementsBeOne Medicines Completes First-in-Human Study of New B7H3 Cancer Drug
21h ago
ONC
AI Models Turn Cautious on BeOne Medicines (ONC) as Valuation and Technicals Weigh
PremiumAI Analyst Ratings
AI Models Turn Cautious on BeOne Medicines (ONC) as Valuation and Technicals Weigh
4d ago
ONC
BeOne Medicines Halts Early KRAS Trial, Resetting Expectations in a Crowded Oncology Race
PremiumCompany Announcements
BeOne Medicines Halts Early KRAS Trial, Resetting Expectations in a Crowded Oncology Race
6d ago
ONC
Zymeworks and BeOne: Long‑Term Cancer Study Update Supports Durable Drug Story
PremiumCompany Announcements
Zymeworks and BeOne: Long‑Term Cancer Study Update Supports Durable Drug Story
6d ago
ONC
ZYME
BeOne Medicines price target raised to $436 from $425 at RBC Capital
PremiumThe Fly
BeOne Medicines price target raised to $436 from $425 at RBC Capital
7d ago
ONC
New Combo Trial in Esophageal Cancer: What LBL-007’s Phase 2 Update Means for ONC Investors
PremiumCompany AnnouncementsNew Combo Trial in Esophageal Cancer: What LBL-007’s Phase 2 Update Means for ONC Investors
12d ago
ONC
BeOne Medicines’ combination shows improved survival in adenocarcinoma
Premium
The Fly
BeOne Medicines’ combination shows improved survival in adenocarcinoma
13d ago
ONC
BeOne Medicines Advances First-in-Human Solid Tumor Trial With BG-C0979
Premium
Company Announcements
BeOne Medicines Advances First-in-Human Solid Tumor Trial With BG-C0979
13d ago
ONC
BeOne Medicines Pits New Breast Cancer Drug Against CDK4/6 Leaders in Phase 3 Test
PremiumCompany Announcements
BeOne Medicines Pits New Breast Cancer Drug Against CDK4/6 Leaders in Phase 3 Test
18d ago
ONC
BeOne Medicines Halts Early Lung Cancer Trial, Resetting Expectations for EGFR Pipeline
PremiumCompany Announcements
BeOne Medicines Halts Early Lung Cancer Trial, Resetting Expectations for EGFR Pipeline
18d ago
ONC
BeOne Wins FDA Nod for BEQALZI Lymphoma Therapy
PremiumCompany Announcements
BeOne Wins FDA Nod for BEQALZI Lymphoma Therapy
25d ago
8K
ONC
BeOne Medicines price target raised to $367 from $364 at Leerink
PremiumThe Fly
BeOne Medicines price target raised to $367 from $364 at Leerink
25d ago
ONC
BeOne Medicines’ Beqalzi granted accelerated approval by FDA
PremiumThe FlyBeOne Medicines’ Beqalzi granted accelerated approval by FDA
27d ago
ONC
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
Premium
The Fly
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
1M ago
ONC
BeOne Medicines price target raised to $409 from $405 at Barclays
Premium
The Fly
BeOne Medicines price target raised to $409 from $405 at Barclays
1M ago
ONC
BeOne Medicines price target raised to $420 from $410 at Guggenheim
PremiumThe Fly
BeOne Medicines price target raised to $420 from $410 at Guggenheim
1M ago
ONC
BeOne Medicines reports Q1 adjusted EPS $3.24 vs. $1.22 last year
PremiumThe Fly
BeOne Medicines reports Q1 adjusted EPS $3.24 vs. $1.22 last year
1M ago
ONC
BeOne Medicines raises FY26 revenue view to $6.3B-$6.5B from $6.2B-$6.4B
PremiumThe Fly
BeOne Medicines raises FY26 revenue view to $6.3B-$6.5B from $6.2B-$6.4B
1M ago
ONC
AMD downgraded, Airbnb upgraded: Wall Street’s top analyst calls
PremiumThe Fly
AMD downgraded, Airbnb upgraded: Wall Street’s top analyst calls
1M ago
AMD
BDX
BeOne Medicines initiated with an Overweight at Wells Fargo
PremiumThe FlyBeOne Medicines initiated with an Overweight at Wells Fargo
1M ago
ONC
BeOne Medicines: FDA grants Priority Review to sBLA for tevimbra/ziihera combo
Premium
The Fly
BeOne Medicines: FDA grants Priority Review to sBLA for tevimbra/ziihera combo
1M ago
ONC
BeOne Medicines price target lowered to $411 from $412 at Truist
Premium
The Fly
BeOne Medicines price target lowered to $411 from $412 at Truist
2M ago
ONC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >